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ABSTRACT 
The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has 
been characterized and actionable or targetable genomic alterations have been identified. 
However, targeted therapies have very limited activity in unselected SCCHN and the current 
treatment strategy is still based on tumor location and disease stage and not on tumor 
biology.  
Trying to select upfront the patients who will benefit from a specific treatment might be a 
way to improve patients’ outcome. With the objective of optimizing the activity of targeted 
therapies and immunotherapy, we have designed an umbrella biomarker-driven study 
dedicated to recurrent and/or metastatic SCCHN patients (EORTC-1559-HNCG, 
NCT03088059). 
In this paper, we review the different trial designs for biomarker-driven studies with their 
respective advantages and opportunities but also the potential pitfalls that led to the design 
of the EORTC-1559-HNCG protocol.  We also discuss the scientific and logistic challenges of 
biomarker-driven trials. 
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KEY MESSAGE  
SCCHN harbors potential therapeutic targets but the use of targeted drugs in an unselected 
population is disappointing. We review the existing biomarker-driven trials and introduce 
the EORTC-HNCG-1559 trial, an approach using a common screening platform to guide a 
personalized, biomarker-based treatment strategy for recurrent/metastatic SCCHN. 
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Introduction 
Squamous cell carcinoma of the head and the neck (SCCHN) is the seventh most common 
malignancy [1]. The main risk factors are smoking and alcohol consumption, which are 
responsible for the majority of SCCHN occurring in the oral cavity, pharynx, and larynx. 
Another risk factor for oropharyngeal cancer (OPC) is the human papillomavirus (HPV). 
Tobacco and/or alcohol-induced SCCHN and HPV-related OPC are two separate entities with 
different clinical and molecular features [2-4].  
 
Less than 60% of the patients with locally-advanced SCCHN remain disease-free at 3 years, 
despite a multimodal treatment combining surgery and/or (chemo)radiation [5]. Patients 
with recurrent/metastatic disease that are not amenable to radiotherapy or surgery have a 
median survival of 10-12 months. Platinum-based chemotherapy in combination with 
cetuximab improves overall survival (OS) in the first-line treatment of incurable disease [6]. 
Nivolumab increases OS of patients who progress after platinum therapy [7]. Pembrolizumab 
is also approved in the same indication by the Food and Drug Administration (FDA) [8]. No 
standard of care exists for patients who progress after platinum-therapy and anti-
programmed cell death protein 1 (PD-1) compounds. 
 
The current treatment strategy of patients with SCCHN is still based on tumor location and 
disease stage and not on tumor biology [4, 9, 10]. Targeted therapies have shown 
disappointing results [11-13]. Trying to select upfront the patients who will benefit from a 
specific treatment might improve the outcome. The European Organization for Research and 
Treatment of Cancer (EORTC) is conducting the EORTC-1559-HNCG trial, the first 
international biomarker-driven umbrella trial in recurrent SCCHN.  In this paper, we will 
review the different trial designs for biomarker-driven studies with their respective 
advantages and opportunities but also the potential pitfalls that led to the design of the 
EORTC 1559 protocol.  We will also discuss the scientific and logistic challenges of this trial. 
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Lessons learned from previous biomarker-driven studies  
Study designs  
 “Master protocol” terminology refers to a framework in which several (sub)studies that 
investigate multiple therapies are operated in parallel under one ‘overarching’ master 
protocol [14]. Master protocols include two different study designs: basket and umbrella 
trials. Table 1 summarizes the opportunities and drawbacks of these designs.  
 
Basket trials are biomarker-driven clinical trials that include patients based on pre-defined 
specific molecular tumor abnormalities, irrespective of tumor origin and histology (Table 2). 
One of the advantages of this histology agnostic approach is to investigate the activity of 
targeted drugs across different cancer types, even in rare cancers for which clinical trials do 
not exist. They also offer the possibility to target low incidence molecular alterations.  
 
Umbrella trials are biomarker-driven clinical trials that are histology specific, investigating 
different therapeutic interventions in a single cancer type (Table 3). A histology specific 
approach is interesting to avoid the heterogeneity due to different biology across various 
tumor types. 
 
Strategy trials investigate if selecting the treatment based on molecular alterations results 
in superior outcome compared to standard therapy, independently of the drug, the disease, 
and the studied biomarker(s). 
 
Molecular screening programs have been implemented to facilitate the access to precision 
medicine trials. These screening initiatives can be histology-agnostic or histology-specific. 
 
Theranostic and molecular screening tools  
Different diagnostic tests are routinely used to predict the activity or resistance of some 
targeted therapies. Most of them are evaluated on tumor biopsies, although liquid biopsies 
are entering into the clinic (e.g. Epidermal Growth Factor Receptor (EGFR) T790M mutation 
in non-small cell lung cancers (NSCLC)). Biomarkers can be evaluated at the proteomic level 
such as the estrogen receptor status assessed by immunohistochemistry (IHC) but also at the 
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genomic level such as Human Epidermal Receptor-2 (HER2) amplifications or EGFR activating 
mutations.  
 
The tumor molecular profile has been obtained in 74% to 93% of screened patients in 
biomarker-driven clinical trials [16, 18-23]. Most of them use DNA sequencing on tumor 
biopsies. Reproducibility and reliability of the molecular screening tools are important. Most 
of the trials use certified laboratories, but the analysis is not always centralized. In these 
cases, some trials performed an inter-laboratory analytical validation before starting the trial 
[24] or validated the assay [25].  
 
A fresh biopsy is probably more reliable than an archival one. Indeed, the cancer molecular 
profile can change during disease evolution [26]. IMPACT [18, 21] used archival paraffin-
embedded tissue (FFPE). In the LUNG-MAP trial [27] and LUNG-MATRIX trial [23], both 
archival or fresh-taken tissues are accepted. In the MOSCATO 01 [20], NCI-MPACT [15], NCI-
MATCH [15], BATTLE [16], and SHIVA [17] trials, a fresh tumor biopsy has/had to be taken for 
the trial purpose.  
 
Actionable genomic alteration frequency and enrolment rate 
According to ESMO glossary [28], targetable genomic alteration encodes an altered protein 
against which a drug exists or can be synthesized and an actionable genomic alteration 
includes both targetable alterations and genomic alterations that cannot be directly targeted 
but that lead to dysregulation of a pathway in which there are possible targets.  
 
The percentage of patients that had an actionable genomic alteration identified through 
screening programs ranged from 46% to 63% [18, 20, 21, 29]. However, the number of 
patients who were finally treated with a matched targeted therapy were low: 13%, 16%, and 
19% in SAFIR01 [29], IMPACT (first published report [21]), and MOSCATO 01 [20], 
respectively. This number increased to 27% in the most recent IMPACT publication [18], 
probably related to the extension of the screening panels. Different reasons may explain 
these low enrolment rate: tumor tissue issues, decline in the performance status or rapidly 
progressing disease, the absence of a targetable event, and the access to matched clinical 
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trials or drugs. As IMPACT and the MOSCATO 01 were screening programs, patients were 
referred to enrolling clinical trials with obvious limitations in the treatment possibilities. 
 
A way to partially solve these issues is to include the access to drugs into the clinical trial 
design. The NCI-MATCH basket trial pre-planned the access to some targeted compounds. 
However, only 12% of the patients were finally enrolled in the trial [22].  This low enrolling 
rate might be due to the low incidence of the targeted variants since only 18% of the 
screened tumors were found to have a genomic alteration that matched one of the 30 
treatment arms. In contrast, in BATTLE and LUNG-MAP, two umbrella trials for NSCLC, 75% 
and 37% of the patients were included in one of the sub-studies, respectively [16, 27]. The 
number of treated patients is higher in these two last trials due to a pre-planned access to 
matched targeted therapies. In addition, for the Battle trial, the molecular profile strategy 
was disease-specific and adapted to NSCLC, explaining the high prevalence of some of the 
investigated biomarkers.  
 
Treatment efficacy in Master protocols 
Treatment selection based on DNA biomarkers has proven its efficiency: anti-HER2 therapies 
for HER2 amplified breast cancer [30] and EGFR or pan-HER inhibitors for EGFR mutated 
NSCLC [31]. Pembrolizumab has been approved, independently of the tumor type, for 
microsatellite instability-high and mismatch repair deficient cancers [32] as well as for the 
first-line treatment of metastatic NSCLC with high PD-L1 expression [33].  
 
Different endpoints are used in biomarker-driven trials. In MOSCATO 01 [20], the primary 
endpoint was the progression-free survival (PFS) ratio calculated for each patient, that must 
be > 1.3 to define clinical benefit (PFS ratio = PFS on the molecular-profile selected 
therapy/PFS on prior therapy). The approach is judged efficient if it modifies the natural 
history of the disease and is associated with a longer PFS than the previous line of 
treatment. Thirty-three percent of patients treated with a targeted therapy had a PFS ratio > 
1.3. However, the number of patients who benefited from the personalized approach 
represented only 7% of the screened patients.  
In IMPACT, the clinical outcomes of patients with molecular aberrations treated with 
matched therapy were compared with those of consecutive patients who were not treated 
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with a matched therapy. They reported a better objective response rate (ORR) (11% vs 5%), 
a longer failure-free survival (3.4 vs 2.9 months), and a longer OS (8.4 vs 7.3 months) in the 
matched group [18]. The clinical benefit rate in the matched group, defined as the 
proportion of patients with either a stable disease lasting more than 6 months or a partial 
response or complete response, was 29% (111/381) as compared to 24% (56/238) in the 
non-matched group. However, only 8% of the whole population finally experienced a clinical 
benefit. The use of non-optimal targeted drugs or sub-optimal dosages in phase 1 trials, and 
sometimes the level of evidence concerning the investigated biomarker(s) may explain the 
limited treatment efficacy observed.  
 
In MyPathway basket trial [34], the ORR was 23% in 14 different tumor types, a clinically 
significant result for advanced refractory disease. In the SUMMIT trial [35], a basket trial 
studying neratinib in patients with a tumor harboring either HER2 or HER 3 mutations, the 
primary endpoint was reached only for breast cancer, and not for lung, bladder, and 
colorectal cancers, underlining the importance of the histology and the tissue of cancer 
origin. In BATTLE [16], the 8-week disease control rate and ORR were 46% and 4%, 
respectively. The first data of the ongoing Lung-MAP trial reported an ORR of 4-7% for the 
first 3 biomarker-driven cohorts [27].  
 
The SHIVA trial was the first randomized trial comparing a molecularly targeted therapy 
based on tumor molecular profiling versus conventional therapy for advanced cancer [17]. 
This study tested the overall strategy of a biomarker-driven treatment approach versus 
standard therapy. The trial did not meet its primary endpoint (PFS). Several reasons could 
explain this overall negative result. First, they used drugs that were marketed in France at 
that time and not necessarily the best in class to target the molecular alteration identified. 
Second, the experimental arm was also heterogeneous with multiple drugs and various 
tumor types. This could have blinded the benefit of some drugs in some specific cancer(s). 
The ongoing NCI-MPACT trial [15] is also a strategy trial. To avoid a negative trial linked with 
inadequate target modulation by the selected agents, all the targeted agents used in NCI-
MPACT have been validated to engage their purported targets and have at least an 
established phase II dose.  
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Biomarker-driven studies for SCCHN 
Only a few biomarker-driven trials are dedicated to SCCHN (table 4). Some phase II trials are 
selecting patients upfront based on a rare specific genomic alteration (HRas proto-oncogene 
(HRAS) mutations or Fibroblast Growth Factor Receptor (FGFR) 
mutations/amplifications/translocations). However, these trials offer only one potential 
therapeutic option for the very low percentage of patients harboring these rare genomic 
events. This results in a high rate of screening failure. There is another ongoing trial in Korea 
assessing personalized therapy for recurrent/metastatic SCCHN and oesophageal cancer 
(NCT03292250) where patients are allocated to different treatment arms after first line 
platinum-based therapy according to molecular characterization.  
 
Actionable or targetable genomic alterations in SCCHN 
Next generation sequencing (NGS) technologies have identified potentially 
actionable/targetable genomic alterations in SCCHN [4, 9, 10]. Targetable genomic 
alterations in HPV-negative SCCHN include events in genes related to kinase growth factor 
family receptors or their downstream molecular pathways: EGFR (15%), FGFR 1-3 (14%), 
HER2 (5%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) 
(34%), and HRAS (5%). HPV-negative SCCHN has also potentially actionable cell cycle 
genomic alterations: TP53 mutation (70%), cyclin D1 (CCND1) amplification (20-30%), and 
CDKN2A inactivation (80-90%). In HPV-positive OPC, where the oncoprotein E6 and E7 
inactivate respectively p53 and Rb, PIK3CA amplifications/mutations are found in 56% 
whereas the other genomic alterations are rare.  
The EORTC-1559-HNCG trial (UPSTREAM: Personalized 
STrategy for REcurrent And/or Metastatic SCCHN)  
Our main objective was to design a biomarker-driven study dedicated to SCCHN patients. 
Below, we describe the overall study design as well as the different treatment cohorts. 
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EORTC-1559-HNCG design 
The EORTC-1559-HNCG trial is a biomarker-driven umbrella trial that enrolls patients with 
recurrent/metastatic SCCHN, progressing after first-line platinum-based chemotherapy. Each 
patient must undergo a fresh tumor biopsy. NGS is performed to identify somatic mutations 
and copy number alterations with a custom panel that has been designed for the trial. This 
panel covers 13 oncogenes and tumor suppressor genes: EGFR, HER2, TP53, PIK3CA, CCND1, 
NRAS, KRAS, HRAS, PTEN, FGFR1, FGFR2, FGFR3, and cMET. The analysis also includes p16 
(p16 positive = Histo-score ≥ 210) and PTEN (PTEN High = Histo-score > 150) determined by 
IHC [36]. mRNA FGFR expression is evaluated by NGS.  All these analyses are performed 
centrally in an ISO 15189 certified laboratory (OncoDNA, Belgium). 
Based on the molecular alterations identified, each patient is allocated to one of the cohorts. 
If the patient is not eligible for one of the biomarker-driven cohorts, he/she is included in 
one of the immunotherapy cohorts. The global design of the trial as well as the molecular 
rules for treatment allocation and prioritization are depicted in figures 1 and 2. 
 
The full protocol includes a core protocol and several addenda. The core protocol describes 
the overall study design, the objectives and endpoints, the inclusion/exclusion criteria, the 
study flow chart, the statistical hypotheses, the data analysis plan, and the biobanking 
processes. For each experimental treatment, there is one separate addendum that contains 
the confidential information related to the drug. The national health regulatory authorities, 
the ethical committee, and the investigators have access to the core protocol and all the 
addenda. The pharmaceutical companies have access to the core protocol but they can view 
and comment only the addendum/addenda concerning the cohort(s) for which they are 
supporting.  
 
EORTC-1559-HNCG biomarker-driven and immunotherapy cohorts 
 
Each patient cohort is designed as a phase II study with its own statistical hypothesis (Table 
5). The primary endpoint is either ORR or PFS rate. Sample sizes vary from 32 to 76 patients 
across cohorts. The study can be amended to add other cohorts based on drug availabilities 
or other biomarker hypotheses.  
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Pan-human epidermal growth factor receptor (HER) inhibitor cohorts 
EGFR mutations/amplifications are described in 15% of HPV-negative SCCHN and HER2 is 
altered (mutation/amplification) in 5%.  
The ORR with cetuximab monotherapy is 13% [37]. In contrast to colon cancer where RAS 
mutations are predictive markers of resistance, RAS alterations are found in only 4% of HPV-
negative SCCHN. Although RAS mutations might also play a role in cetuximab resistance in 
SCCHN [38], other mechanisms including activation of other HERs are involved [39, 40].  
Pan-HER inhibitors target all the dimers forms by HER family and have the potential to 
overcome anti-EGFR therapy resistance caused by cross-talk between EGFR and the other 
HERs. In unselected SCCHN patients who progress after platinum therapy, afatinib, an 
irreversible pan-HER inhibitor, improves PFS compared with methotrexate: median PFS 2.7 
versus 1.6 months [41]. However, afatinib does not increase OS. Biomarkers analyses were 
performed within this trial [36]. Median PFS favored afatinib in patients with p16-negative, 
EGFR-amplified (defined as ≥ 50% of cells with ≥ 4 copies, or ≥1 cell with ≥ 8 copies), HER3-
low (defined as H-score ≤ 50), and PTEN-high (defined as H-Score > 150) tumors. In the 
MCC15780 trial where 38 SCCHN patients were treated with cetuximab [42], PFS was also 
significantly increased in PTEN-high tumors compared to PTEN-low tumors [43].  The fact 
that afatinib seemed to be more active in case of HER3-low and PTEN-high disease suggests 
that pan-HER inhibitors could be more active when the PI3K pathway is not or less activated. 
Cetuximab-naïve patients with p16 negative tumor had also a significant benefit from 
afatinib (ORR: 27%).  
We designed two biomarker-driven cohorts in the EORTC-1559 trial where the patients are 
randomized between afatinib or investigator’s choice. The first cohort includes patients with 
p16 negative SCCHN harboring either an EGFR mutation/amplification or HER2 
mutation/amplification or PTEN high (H-score > 150). We did not include patients with HER3 
low disease as this IHC is not always reproducible [44]. The second cohort includes 
cetuximab-naïve SCCHN patients with p16-negative tumor. SCCHN with any RAS mutations 
are excluded [38]. 
 
Fibroblast growth factor receptor (FGFR) inhibitor cohorts 
FGFRs can activate the RAS-MAPK, PI3K, STAT, and PLCγ pathways [45]. FGFR1 
mutation/amplification are found in 5-10% of HPV-negative SCCHN, while FGFR 3 mutations 
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are more frequent in HPV-induced OPC (1-12%). Genetic alterations of FGFR2 are observed 
in only 2-4%.  
Erdafitinib, a pan-FGFR inhibitor, induced ORR in 24-35% of patients with metastatic 
urothelial cancer harboring FGFR alterations (including activating mutations and 
translocations) [46]. Twenty-four percent of patients with urothelial cancer overexpressing 
FGFR1-3 mRNA achieved ORR with Rogaratinib, another pan FGFR inhibitor [47]. Partial 
responses were also observed in some patients with squamous cell lung cancer, SCCHN, and 
adenoid cystic carcinoma [48]. Interestingly, some responding patients had elevated tumor 
FGFR3 mRNA levels without corresponding genomic alterations. The prevalence of FGFR1-3 
mRNA positivity among 46 SCCHN patients was 56.5% [49].  
We will investigate Rogaratinib in cases of high FGFR mRNA levels assessed by NGS.  
 
Cell cycle inhibitor cohort 
The vast majority of HPV-negative SCCHN harbors genetic alterations (TP53 mutations, 
CCND1 amplification, and p16 inactivation) that enable them to circumvent the mitotic 
checkpoints through aberrant cyclin-dependent kinase (CDK) activation. Since p16 
inactivates CDK4/6 whereas cyclin D1 activates CDK4/6, there is a rationale to test CDK4/6 
inhibitors in patients with p16 negative and CCND1-amplified SCCHN. Palbociclib in 
combination with cetuximab has been investigated in recurrent SCCHN with promising 
preliminary results (ORR: 35%) [50]. However, palbociclib monotherapy has not been 
investigated in SCCHN. 
We will investigate palbociclib in patients with p16 negative tumors harboring CCND1 
amplification. 
 
Poly ADP ribose polymerase (PARP) inhibitor cohorts 
DNA repair deficiency increases sensitivity to platinum-based chemotherapy and PARP 
inhibitors [51]. A comprehensive analysis for homologous recombination deficiency (HRD) 
was performed and HRD was associated with ovarian, lung, SCCHN, and bladder cancer. 
Preclinical studies have shown that HPV-positive SCCHN have DNA double strand repair 
defects responsible for increased sensitivity to the PARP inhibitor veliparib [52]. These data 
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support the two patient cohorts that will investigate niraparib, another PARP-inhibitor, in 
p16-positive OPC  and in platinum-sensitive p16 negative SCCHN.  
 
Immunotherapy cohorts 
PD-1/PD-L1 blockers have activity in SCCHN but the 2-year’s OS rate is still low: 16.9% [53]. 
Therefore, other immunotherapy approaches have to be investigated. 
HLA-E is a non-classical major histocompatibility complex molecule that constitutes a way for 
cancer cells to escape immune surveillance. HLA-E is highly expressed in 70% of SCCHN [54]. 
HLA-E binds to NKG2A receptor on NK cells and T-lymphocytes to inhibit the cytotoxic 
functions of CD8+ T lymphocytes and NK cells. Monalizumab is a human IgG4 antibody 
targeting the NKG2A receptor. In the first immunotherapy cohort, patients will receive 
monalizumab monotherapy. In the second immunotherapy cohort, patients will be 
randomized to receive the combination of durvalumab and monalizumab versus 
monalizumab monotherapy versus physician’s choice. 
 
EORTC1559 Feasibility 
 
The trial is open for inclusion since December 2017. On 19 July 2018, 19 sites are open in 3 
countries.  64 patients have been screened, 24 included in one of the biomarkers cohorts 
and 23 in one of the immunotherapy cohorts. The turnaround time between the biopsy and 
the molecular diagnosis provided by the central lab is 10 calendar days. 
Discussion 
The EORTC-1559-HNCG trial is the first European international umbrella trial assessing a 
personalized treatment strategy for patients with recurrent/metastatic SCCHN. We 
hypothesize that this approach can improve patients’ outcome.  
The trial design has different strong points: one single protocol with pre-planned access to 
matched targeted therapies, one fresh tumor biopsy to deal with tumor evolution over time, 
an ISO-certified central laboratory, well-defined biomarker hypotheses, and the possibility to 
have a never-ending protocol with the opportunity of adding new cohorts.   
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Besides the inherent complexity of such trials, numerous logistic and scientific challenges 
were encountered when designing this protocol. 
Although the pharmaceutical companies accepted the concept of having only one protocol 
including the different compounds, complex negotiations were crucial to successfully 
achieve that all stakeholders agreed (i) to standardize the processes, (ii) to accept the pre-
defined protocol structure, (iii) to use the central biomarker laboratory, (iv) to match the 
company interests with the academic wishes, and (v) to align all the companies on the same 
protocol wording in particular for the inclusion/exclusion criteria. The protocol was 
submitted in 4 different countries (Belgium, France, Italy, United Kingdom) and will be 
submitted in Germany to both competent authorities (CA) and applicable ethics committees 
(EC). Overall, the study was well received by the CA and EC without major comments on the 
study design. The main question received from EC was concerning the criteria to allocate 
patients to the different cohorts. Regarding the regulatory strategy, having all those cohorts 
in only one study simplifies the submission process, as it requires only one initial clinical trial 
application to each CA and one initial request of opinion to each EC. Also, each amendment 
can group modifications concerning more than one cohort at the same time. If we had 
considered each cohort as one trial, different submissions would have been necessary, 
increasing the regulatory workload and probably time for activation. As separate trials, the 
advantage would have been that the current cohorts could be opened/closed independently 
across the countries without the need of a main protocol amendment. In addition, the 
liaison with the stakeholders would be easier, as the number of stakeholders per trial would 
be significantly reduced.  
The new European clinical trials regulation [55] fully in application next year might bring a 
novel perspective for studies with a complex design. Multiple member states will participate 
on the coordinated assessment of some sections of the dossier, ensuring that consolidated 
communication reaches the applicant. This may reduce the volume of correspondence and 
facilitate the management of any protocol modifications if they are required. 
Several challenges remain. Optimal management of country-specific documents adaptation 
and effective communication with the stakeholders might be the key to ensure fulfillment of 
adequate deadlines and quick activation of new cohorts to follow the fast advancing head 
and neck cancer research field. 
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At the scientific level, the study is still missing some treatment arms that target important 
genetic aberrations. PIK3CA alterations occur in 16 to 34% of HPV-negative patients and in 
up to 56% of HPV-positive patients. Patient-derived SCCHN tumor xenografts with PIK3CA 
activating mutations are sensitive to mTOR/PI3K inhibitors [56] and, in the BERIL-1 trial, 
buparlisib improved OS when added to paclitaxel [57].  Among other interesting targets, 
there is a scientific rationale to test Farnesyl transferase inhibitors in the 5% of SCCHN 
harboring HRAS mutations or WEE1 inhibitors in TP53 mutated tumors.  
 
In the current design, immunotherapy cohorts are not linked to biomarker(s). Among others, 
HPV-positivity, PD-L1 overexpression, in-frame or frameshift alterations of specific tumor 
suppressor genes, and mutational burden are potential biomarkers that have been 
associated with a higher efficacy of immunotherapy in SCCHN [7, 8, 58]. However, these 
predictive markers are far to be optimal. Umbrella trials represent an ideal platform to 
further investigate the predictive value of immune biomarkers. 
 
We cannot deny that tumor heterogeneity that can cause treatment resistance is not 
addressed by the use of targeted compounds in monotherapy.  Therefore, we also collect 
whole blood, plasma as well as tumor biopsies for translational research. Analyzing these 
biological samples will give us more insight on the genetic landscape of recurrent/metastatic 
SCCHN, which may lead to the discovery of new therapeutic targets, and may help to 
investigate more precisely the utility of liquid biopsy. Translational research will also provide 
information regarding drug resistance mechanisms and will help us to develop new 
combination treatments that are able to tackle them.   
 
A finding of biomarker-driven studies is the low number of patients who benefit from this 
approach. This suggests that for heterogeneous cancers with multiple potential oncogenic 
drivers, biomarkers assessed only at the DNA level may not predict drug responses reliably. 
The signification of some genomic alterations can vary from one cancer histology to another. 
Therefore, for further developments, we will have to take into account several others 
parameters such as the phenotype (e.g. gene expression/proteomic profiles) and the tissue 
of cancer origin [59].  
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In conclusion, precision medicine remains a major challenge for the medical community. 
Large efforts are needed to optimize the study designs, the theranostic tools, and the trial 
logistics. Designing biomarker-driven studies requires close collaboration with country 
competent authorities, ethics committees, and pharmaceutical companies to reduce the 
administrative burden and facilitate the processes linked with the design and conduct of 
such clinical trials. 
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Figure legends:  
Figure 1. General design of the EORTC1559 umbrella trial 
Figure 2. Prioritization algorithm for the allocation to different patient cohorts 
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Table 1. Advantages and pitfalls of “biomarker-driven” clinical trial designs  
 ADVANTAGES DISADVANTAGES 
MASTER PROTOCOLS   
BASKET trials  
« histology agnostic » 
 
can include rare cancer types  
 
can target low incidence 
actionable/targetable molecular 
alterations  
 
assumes that molecular biology can 
replace histology and that a specific 
genetic alteration has the same 
signification across different tumor 
types 
UMBRELLA trials 
« histology specific » 
targets molecular alterations in one 
cancer type and avoid heterogeneity 
due to multiple cancer histologies  
 
enables to get more conclusive results 
for one tumor type. 
 
feasibility limited for rare cancers 
SCREENING PROGRAMS have the potential to identify an 
actionable/targetable genetic 
alteration  
 
can facilitate the access to early 
development clinical trials 
if an actionable/targetable alteration 
is present, the specific drug is not 
always available with the risk that a 
low number of patients finally 
benefits from this program 
 
STRATEGY TRIALS  have the potential to identify an 
actionable/targetable genetic 
alteration  
 
Effect of the strategy can be diluted 
by less effective target-drug pairs 
 
Table 2: Selected histology agnostic biomarker-driven approaches 
Study Tumor Study design Biomarker Methodology Endpoint Identification of target 
and number of treated 
patients 
Results and impact 
on outcome 
IMPACT [18, 
21] 
All, refractory 
advanced cancer 
Screening 
program 
Archival (FFPE) 
 
PCR-based 
sequencing for 
selected genes 
(PIK3CA, BRAF, 
KRAS and NRAS, 
EGFR, KIT, GNAQ, 
TP53 and MET), 
Sanger sequencing 
for RET analysis, 
IHC for PTEN loss of 
expression and 
FISH for ALK 
translocation 
 
Update 2017: 
Sequencing by NGS 
at MD Anderson 
(11, 46 or 50 genes 
depending on the 
panel), Foundation 
Medicine (182 
genes), Knight 
Diagnostics (48 
genes) or other 
CLIA-certified 
laboratories 
 
! Gene panels of 
different sizes were 
used for MP! 
Screening route to 
phase 1 
 
Assignment to 
phase 1 clinical 
trial based on the 
identification of 
MA 
Clinical outcome 
of pts with MA 
treated with 
matched 
therapy vs pts 
not treated with 
matched 
therapy 
- 1144/1283 pts had 
adequate tissue for 
molecular analysis 
(89.2%) 
- 460/1144 analyzed pts 
had 1 or more MA 
(40.2%) 
- 211/460 (45.8%)treated 
with matched therapy = 
16.4% of total population 
 
Update 2017: 
- 1179/1436 pts had 1 or 
more MA (82%) 
- 914/1179 had 1 or more 
targetable alteration 
(77.5%) 
- 390/637 (45.8%)pts with 
at least 1 alteration that 
were treated, received 
matched therapy = 27% 
of total population 
 
Analysis on 379 with 
1 MA:  
175 pts treated with 
matched therapy vs 
116 non-matched 
(88 pts excluded 
from clinical 
outcome analysis):  
- ORR:  27% in 
matched therapy vs 
5% (p<0.0001) 
- SD ≥ 6mo: 23% vs 
10% 
- OS: 13.4 mo vs 9 
mo (p=0.017) 
 
Update 2017: 
- ORR: 11% vs 5% 
(p=0.0099) 
- SD ≥ 6mo + CR +PR 
: 29%vs 24% 
- FFS: 3.4 vs 2.9 mo 
(p=0.0015) 
- OS: 8.4 vs 7.3mo 
(p=0.41) 
SHIVA trial 
[17] 
All, refractory 
advanced cancer 
Strategy trial 
 
Multicentre, 
open-label, 
proof-of-
concept, 
randomized, 
phase II trial 
New biopsy 
 
Mutations by 
targeted NGS 
(AmpliSeq cancer 
panel) 
CNA by Affymetix 
IHC for oestrogen, 
progesterone and 
androgen receptors 
pts with MA in 
one of 3 molecular 
pathways that 
could be matched 
with 11 different 
targeted agents 
were randomized 
between the 
targeted therapy 
and control arm 
PFS  - 716/741 screened pts 
underwent tumor sample 
- 293/741 screened 
patients had at least 1 MA 
matching one therapy 
(40%) 
- 196/741 pts were 
randomized (26%) 
Negative trial:  
Median PFS was 2.3 
mo in the 
experimental group 
vs 2.0 mo in the 
control group 
(p=0.41) 
MOSCATO 
01 trial [20] 
All, advanced cancer Screening 
program 
 
Single-centre, 
singe-arm, 
open-label, 
prospective 
clinical trial  
New biopsy (Fresh-
frozen) 
 
At the start of trial: 
targeted 
sequencing (first 
Ion Ampliseq 
Cancer Panel 
covering 40 genes, 
then the Ion 
Ampliseq Cancer 
Hotspot Panel v2.0 
in 50 genes and 
finally an Ion 
AmpliSeq custom 
design covering 75 
genes)  aCGH 
analysis and IHC for 
phospho-MET 
 
RNA sequencing 
and whole-exome 
sequencing were 
added during the 
trial 
Screening route to 
phase 1/2 
 
Assignment to 
phase 1 clinical 
trial based on the 
identification of 
MA 
Evaluate the 
clinical benefit 
as measured by 
% of pts 
presenting PFS 
on matched 
therapy (PFS2) 
1.3-fold longer 
than the PFS on 
prior therapy 
(PFS1) 
- 948/1035 included pts 
underwent biopsy 
- MP obtained in 843/948 
pts (89%) 
- 411/843 pts had a MA 
(49%) 
- 199 pts were treated 
with a targeted therapy = 
19% of total population 
PFS2/PFS1 ratio > 1.3 
in 63/199 pts treated 
with targeted 
therapy (33%) = 7% 
of successfully 
screened pts. 
CREATE trial 
[60-63] 
Advanced tumours 
characterized by 
MET and/or ALK 
alterations (papillary 
renal-cell carcinoma 
type 1, alveolar soft 
part 
sarcoma, clear-cell 
sarcoma, anaplastic 
large-cell 
lymphoma, 
inflammatory 
myofibroblastic 
tumour, and 
alveolar 
rhabdomyosarcoma) 
 
Multinational, 
multitumour, 
prospective 
phase II clinical 
trial  
Tumour containing 
tissue block (FFPE) 
from the primary 
tumour and/ 
or metastatic site: 
sequencing 
(bidirectional 
Sanger sequencing 
method of only 1 
gene) (MET), FISH 
for copy number 
status 
Treatment with 
crizotinib in the 
different patient 
cohorts  
ORR No biomarker-positivity 
needed for entering the 
trial 
Results published 
per histology 
NCI-MPACT 
[15] 
All, advanced solid 
tumor 
Strategy trial 
 
Double-blind, 
randomized trial 
New biopsy  
 
NGS of > 380 
unique actionable 
variants in 20 genes 
Pts with specific 
mutation are 
randomized in 2:1 
ratio to receive 
targeted therapy 
vs control (not 
specifically 
targeting the 
detected 
mutation/pathway 
of interest) 
ORR and 4-
month PFS 
NA,  
270 evaluable pts are 
planned for enrollment. 
 
 
Over 100 patients 
have been screened 
to date, though no 
interim 
analysis results have 
been presented to 
date 
NCI-MATCH 
[15] 
All, advanced solid 
tumors 
Master protocol 
 
Phase II, 
multicenter, 
open-label, non-
randomized 
Basket trial 
New biopsy  
or recent biopsy of 
< 6 months with no 
interim therapy 
 
sequencing assay 
for more than 
4,000 different 
Pts with MA are 
assigned in one of 
predefined 
treatment cohorts 
ORR - successful laboratory 
testing for 93% of pts 
- 18% of screened tumors 
was found to have a 
genetic mutation that 
matched the patient to 1 
of the 30 treatment arms. 
- 998 pts have been 
As of July 2017, 5963 
tumor samples have 
been screened 
variants  
in 143 genes  
 
assigned to treatment, of 
which 69% have enrolled  
(12% of screened 
population) 
 
Mypathway 
[34] 
Advanced refractory 
solid tumor 
harboring MA in 
HER2, EGFR, BRAF 
or Hedgehog 
pathway 
Master protocol 
 
Phase IIa, 
multicenter, 
non-
randomized, 
multiple basket 
study 
MP was not 
conducted as part 
of this study. 
 
 
Pts are assigned to 
specific treatment 
cohorts based on 
the presence of a 
relevant target 
MA 
Investigator-
assessed ORR 
within each 
tumor-pathway 
cohort 
NA, pts were only 
included if testing already 
performed outside the 
clinical trial 
Efficacy analysis 
population: 230 pts 
 
ORR: 23% within 14 
different tumor 
types  
SUMMIT 
[35] 
Solid tumors 
harbouring HER2 
and HER3 mutations 
Master protocol 
 
Multi-cohort 
basket study 
MP was not 
conducted as part 
of the study, locally 
reported HER2/3 
mutations were 
confirmed centrally 
Pts with HER2-
mutant cohorts 
were enrolled into 
disease-specific 
cohorts and HER3 
mutants into one 
cohort 
Investigator-
assessed ORR 
NA Total: 125 HER2 
mutant pts and 16 
HER3 mutant pts 
 
For HER2 mutant 
tumors, primary 
endpoint was met 
only for breast 
cancer (ORR 32%) 
and not for lung, 
colorectal or 
bladder. 
 
No responses were 
observed in the 
HER3 mutant cohort 
 
Abbreviations 
aCGH: comparative genomic hybridization array, CNA: copy number alteration, DCR: Disease control rate, FFPE: Formalin-fixed, paraffin-embedded, FFS: failure-free survival, FISH: fluorescence in situ hybridization, 
IHC: immunohistochemistry, MA: molecular alteration, mo: months, MP: molecular profile, NGS: Next generation sequencing, ORR: overall response rate, PFS: progression free survival, Pts: patients, vs: versus 
 
 
 
Table 3: Selected histology specific biomarker-driven approaches 
Study Tumor Study design Biomarker Methodology Endpoint Identification of 
target and 
number of 
treated patients 
Results and impact on 
outcome 
The 
BATTLE 
trial [16] 
Non-small 
cell lung 
cancer 
Master 
protocol 
 
Randomized 
phase II, 
single-center, 
open-label 
study 
 
 
Fresh biopsy (FFPE) 
 
Testing of 11 prespecified 
biomarkers: PCR-based 
sequencing for mutations 
(EGFR, KRAS, and BRAF), 
CNA by FISH (EGFR, CCND1), 
and protein expression 
levels by IHC  
Multiples arms: 
5 biomarkers groups with 
different targeted therapies 
 
equal random assignment 
for 97 first pts, and adaptive 
randomization for next 158  
DCR at 8 
weeks 
341pts enrolled: 
299 with 
adequate tissue 
for analysis 
(88%) 
255 pts were 
randomized 
(75%) 
Overall 8w DCR: 46% 
 
Biomarker groups less 
predictive than individual 
biomarkers 
SAFIR01 
[29] 
Metastatic 
breast 
cancer 
Screening 
program 
Fresh biopsy 
 
aCGH for preselected genes 
and Sanger sequencing for 
mutational hotspots on 
PIK3CA and AKT1 
Screening: 
Based on the identified 
genomic alteration, pts were 
treated with targeted 
therapy if possible (within 
clinical trial or not) 
Proportion of 
patients for 
whom a 
targeted 
therapy could 
be offered 
423 pts 
included, biopsy 
obtained for 407 
pts 
Targetable 
alteration in 195 
(46%) 
Therapy could be 
personalized in 55/423 
pts (13%) 
LUNG-
MAP 
master 
protocol 
[27] 
Advanced 
lung 
squamous 
cell 
carcinoma 
Master 
protocol 
 
Phase II-III 
umbrella trial 
Archival FFPE or fresh tumor 
biopsies 
 
FoundationOne NGS assay 
(Foundation Medicine) for 
mutations, amplifications, 
rearrangements (324 genes) 
and some IHC 
Mutiple arms: 
Based on the molecular 
profile, each pt is enrolled in 
a sub-study with matched 
targeted therapy or in non-
match sub-study 
ORR 1392 pts 
registered to the 
screening 
component 
523 pts 
registered to a 
sub-study (37%) 
First results for 3 
biomarker driven cohorts 
(S1400B, S1400C and 
S1400D): 
ORR 4-7% 
Cohorts closed due to 
futility at interim analysis  
 
S1400A 
(immunotherapy): 16% 
ORR 
 
Other sub-studies 
ongoing 
 The 
National 
Lung 
Matrix 
[23] 
Advanced 
NSCLC 
Master 
protocol 
 
Phase II 
umbrella trial  
Pre-screening of tumor 
biopsies through the 
Stratified Medicine 
Programme 2 (take place in 
parallel with the patient 
receiving first line 
treatment): adaptable 28-
gene NGS sequencing 
platform designed by 
Illumina covering the range 
of molecular abnormalities 
being targeted  
Multiples arms (8 
investigational medicinal 
products, within 21 distinct 
cohorts) 
Patients are allocated to the 
appropriate targeted 
therapy according to the 
molecular genotype of their 
cancer 
 
Bayesian adaptive design 
 
 “No actionable mutation 
arm” for patients without 
specific eligibility for one of 
the targeted genomic 
aberrations  
ORR or PFS As of july 2016: 
- 1664 pts tested 
- 1229 passed 
QC step (74%), 
1098 pts with 
NGS results 
(66%) 
- 731 pts with 
aberration for 
MATRIX (44%) 
- 458 pts (28%) 
with MA and 
eligible (not 
registered) for 
MATRIX  
 
 
As at 9 June 2017, 151 
patients have been 
registered, 125 of these 
patients have received 
targeted treatments 
within the Lung Matrix 
trial. 
No results available per 
cohort.  
 
The Osimertinib cohort 
has been closed for 
recruitment. 
FOCUS4 
[64] 
Advanced 
colorectal 
cancer 
Master 
protocol 
 
Phase II-III 
umbrella trial 
FFPE block taken prior to 
commencement of standard 
chemotherapy 
 
Mutations of some 
preselected genes + some 
IHC, mRNA EREG 
 
Multiple arms 
After induction 
chemotherapy, pts are 
enrolled in different cohorts 
on the basis of MA in the 
tumor, to test different 
targeted agents versus 
placebo or in a no-biomarker 
cohort testing standard 
capecitabine vs placebo as 
maintenance 
PFS NA First results for 1 patient 
cohort (FOCUSD): 
Median PFS 3.48 mo with 
placebo and 2.96mo with 
AZD8931: closed for 
futility 
 
Abbreviations 
aCGH: comparative genomic hybridization array, CNA: copy number alteration, DCR: Disease control rate, FFS: failure-free survival, FISH: fluorescence in situ hybridization, IHC: immunohistochemistry, MA: molecular 
alteration, mo: months, MP: molecular profile, NGS: Next generation sequencing, ORR: overall response rate, PFS: progression free survival, Pts: patients, vs: versus, QC: quality check 
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Table 5. Different patient cohorts of EORTC HNCG 1559 trial 
 
Patient 
Cohort 
Biomarker(s) Targeted 
drug/IO 
Design Sample 
size 
(max) 
Statistical 
hypothesis 
Biomarker-driven patient cohorts 
B1* p16 negative and EGFR 
amplification/mutation 
or PTEN high or HER2 
amplification/mutation 
 
Afatinib Phase II, randomized, 
open-label, multi-
center study 
 
Simon 2 Stage design 
55 H0: PFSR at 16 
weeks = 20% 
H1: PFSR at 16 
weeks = 40% 
B2* p16 negative and 
cetuximab naïve  
Afatinib Phase II, randomized, 
open-label, multi-
center study 
 
Simon 2 Stage design 
55 H0: PFSR at 16 
weeks = 20% 
H1: PFSR at 16 
weeks = 40% 
B3 p16 negative and 
CCND1 amplification 
Palbociclib Phase II, randomized, 
open-label, multi-
center study 
 
Simon 2 Stage design 
55 H0: PFSR at 16 
weeks = 20% 
H1: PFSR at 16 
weeks = 40% 
B4 p16 negative and 
‘platinum-sensitive’ 
Niraparib Phase II, single arm, 
proof-of-concept, 
multi-center study 
 
Simon 2 Stage design 
32 H0: ORR over first 
16 weeks = 5% 
H1: ORR over first 
16 weeks = 20% 
B5 p16 positive 
oropharyngeal cancer 
Niraparib Phase II, single arm, 
proof-of-concept, 
multi-center study 
 
Simon 2 Stage design 
32 H0: ORR over first 
16 weeks = 5% 
H1: ORR over first 
16 weeks = 20% 
B6** FGFR1/2/3 mRNA 
overexpression 
Rogaratinib Phase II, single arm, 
proof-of-concept, 
multi-center study 
 
Simon 2 Stage design 
 
20 H0: ORR over first 
16 weeks = 5% 
H1: ORR over first 
16 weeks = 25% 
Immunotherapy cohorts 
I1 NA Monalizumab Phase II, single arm, 
proof-of-concept, 
multi- center study 
 
Single stage A’Hern 
design 
40 H0: ORR over first 
16 weeks = 3% 
H1: ORR over first 
16 weeks = 15% 
I2 NA Monalizumab 
+ Durvalumab 
Phase II, randomized, 
open-label, multi-
center study 
 
Simon 2 Stage design 
76 H0: ORR over first 
16 weeks = 3% 
H1: ORR over first 
16 weeks = 15% 
*Patients included in the afatinib arms should not have activating mutation in RAS  
** Patients included in the rogaratininb arm should not have activating mutation in RAS or PIK3CA 
 
Abbreviations 
ORR: overall response rate, PFSR: progression-free survival rate 
 
  
 
 
Figure 1. General design of the EORTC1559 umbrella trial  
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Figure 2. Prioritization algorithm for the allocation to different patient cohorts  
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